BeOne Medicines clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
11 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 5 with minor changes only.
- Notable: Investigational Study of BG-75202 Alone and in Combination With Other Agents · Advanced Solid Tumors Enrollment increased: 86 → 186 participants
- Notable: BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma Recruitment opened
- Notable: Tacabrutideg (BGB-16673) · Moderate and Severe Hepatic Impairment Start date pushed from Oct 22, 2026 to Dec 2026
- Minor: Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Trial sites reduced: 150 → 145 locations
- Notable: BG-C477 · Advanced Solid Tumors Primary and study completion pushed from Dec 31, 2027 to Jul 23, 2028
- Minor: KANDELA-302 · BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole · Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease Trial sites expanded: 206 → 241 locations
- Minor: Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma Trial sites reduced: 77 → 74 locations
- Minor: Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults Trial completed
- Notable: Treatment · B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader Sponsor changed: BeiGene to BeOne Medicines
- Notable: Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents · Advanced Solid Tumors Primary and study completion pushed from Sep 30, 2027 to Aug 31, 2028
- Minor: Sonrotoclax · Severe Hepatic Impairment Start date pushed from Oct 15, 2026 to Nov 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-12 | NCT07934069 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food… | Phase 1 | Not Yet Recruiting |
| 2026-11-03 | NCT07911683 Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced… | Phase 2 | Not Yet Recruiting |
| 2026-10-29 | NCT07904845 A Study of BON-C1393 in Adults With Advanced Solid Tumors | Phase 1 | Not Yet Recruiting |
| 2026-10-27 | NCT07896460 A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents… | Phase 1 | Not Yet Recruiting |
| 2026-10-26 | NCT07893535 An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Not Yet Recruiting |
| 2026-10-21 | NCT07887646 A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody… | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 29 | |
| Phase 1/2 | 9 | |
| Phase 2 | 5 | |
| Phase 2/3 | 1 | |
| Phase 3 | 14 |
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 19
Leukemia (12) · Chronic Lymphocytic Leukemia (CLL) (10) · Non-Hodgkin Lymphoma (10) · Mantle Cell Lymphoma (6) · Breast Cancer (4) · DLBCL (4) · Follicular Lymphoma (3) · Gastric Cancer (3) · Liver Cancer (3) · Acute Myeloid Leukemia (AML) (2)
Get alerts when BeOne Medicines's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.